nodes	percent_of_prediction	percent_of_DWPC	metapath
Naloxone—ESR1—uterine cancer	0.351	1	CbGaD
Naloxone—ESR1—Medroxyprogesterone Acetate—uterine cancer	0.147	0.307	CbGbCtD
Naloxone—ESR1—Progesterone—uterine cancer	0.0974	0.203	CbGbCtD
Naloxone—OPRK1—Progesterone—uterine cancer	0.0861	0.18	CbGbCtD
Naloxone—CYP2C8—Medroxyprogesterone Acetate—uterine cancer	0.0372	0.0778	CbGbCtD
Naloxone—CYP2C8—Progesterone—uterine cancer	0.0247	0.0515	CbGbCtD
Naloxone—ABCB1—Progesterone—uterine cancer	0.0167	0.0349	CbGbCtD
Naloxone—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0151	0.0315	CbGbCtD
Naloxone—ABCB1—Dactinomycin—uterine cancer	0.0132	0.0277	CbGbCtD
Naloxone—CYP2C8—Etoposide—uterine cancer	0.011	0.0231	CbGbCtD
Naloxone—CYP3A4—Progesterone—uterine cancer	0.01	0.0209	CbGbCtD
Naloxone—ABCB1—Etoposide—uterine cancer	0.00747	0.0156	CbGbCtD
Naloxone—ABCB1—Doxorubicin—uterine cancer	0.0051	0.0106	CbGbCtD
Naloxone—CYP3A4—Etoposide—uterine cancer	0.00448	0.00935	CbGbCtD
Naloxone—CREB1—exocrine gland—uterine cancer	0.00375	0.0746	CbGeAlD
Naloxone—TLR4—decidua—uterine cancer	0.00351	0.0697	CbGeAlD
Naloxone—TLR4—endometrium—uterine cancer	0.00333	0.0661	CbGeAlD
Naloxone—CYP3A4—Doxorubicin—uterine cancer	0.00305	0.00638	CbGbCtD
Naloxone—ESR1—oviduct—uterine cancer	0.00256	0.0509	CbGeAlD
Naloxone—TLR4—female gonad—uterine cancer	0.00251	0.0499	CbGeAlD
Naloxone—CREB1—myometrium—uterine cancer	0.00208	0.0414	CbGeAlD
Naloxone—CREB1—epithelium—uterine cancer	0.00163	0.0325	CbGeAlD
Naloxone—CREB1—uterine cervix—uterine cancer	0.00162	0.0322	CbGeAlD
Naloxone—TLR4—lymph node—uterine cancer	0.00161	0.032	CbGeAlD
Naloxone—CREB1—smooth muscle tissue—uterine cancer	0.00157	0.0313	CbGeAlD
Naloxone—CREB1—decidua—uterine cancer	0.00154	0.0307	CbGeAlD
Naloxone—CREB1—renal system—uterine cancer	0.00152	0.0301	CbGeAlD
Naloxone—CREB1—endometrium—uterine cancer	0.00146	0.0291	CbGeAlD
Naloxone—CREB1—mammalian vulva—uterine cancer	0.00142	0.0282	CbGeAlD
Naloxone—CREB1—uterus—uterine cancer	0.00135	0.0268	CbGeAlD
Naloxone—CREB1—female reproductive system—uterine cancer	0.00121	0.0241	CbGeAlD
Naloxone—OPRD1—renal system—uterine cancer	0.0012	0.0238	CbGeAlD
Naloxone—CREB1—female gonad—uterine cancer	0.0011	0.0219	CbGeAlD
Naloxone—CREB1—vagina—uterine cancer	0.0011	0.0218	CbGeAlD
Naloxone—OPRK1—female reproductive system—uterine cancer	0.00092	0.0183	CbGeAlD
Naloxone—Injection site reaction—Medroxyprogesterone Acetate—uterine cancer	0.000889	0.0224	CcSEcCtD
Naloxone—ESR1—myometrium—uterine cancer	0.000819	0.0163	CbGeAlD
Naloxone—Hot flush—Progesterone—uterine cancer	0.000766	0.0193	CcSEcCtD
Naloxone—Menopausal symptoms—Progesterone—uterine cancer	0.000759	0.0191	CcSEcCtD
Naloxone—CREB1—lymph node—uterine cancer	0.00071	0.0141	CbGeAlD
Naloxone—SLCO1A2—renal system—uterine cancer	0.000703	0.014	CbGeAlD
Naloxone—Hot flush—Medroxyprogesterone Acetate—uterine cancer	0.000694	0.0175	CcSEcCtD
Naloxone—Menopausal symptoms—Medroxyprogesterone Acetate—uterine cancer	0.000688	0.0173	CcSEcCtD
Naloxone—Irritability—Progesterone—uterine cancer	0.000684	0.0172	CcSEcCtD
Naloxone—ESR1—epithelium—uterine cancer	0.000643	0.0128	CbGeAlD
Naloxone—Nasopharyngitis—Progesterone—uterine cancer	0.000641	0.0161	CcSEcCtD
Naloxone—ESR1—uterine cervix—uterine cancer	0.000637	0.0127	CbGeAlD
Naloxone—Irritability—Medroxyprogesterone Acetate—uterine cancer	0.00062	0.0156	CcSEcCtD
Naloxone—ESR1—smooth muscle tissue—uterine cancer	0.00062	0.0123	CbGeAlD
Naloxone—ESR1—decidua—uterine cancer	0.000607	0.0121	CbGeAlD
Naloxone—ESR1—renal system—uterine cancer	0.000596	0.0119	CbGeAlD
Naloxone—Nasopharyngitis—Medroxyprogesterone Acetate—uterine cancer	0.000581	0.0146	CcSEcCtD
Naloxone—ESR1—endometrium—uterine cancer	0.000577	0.0115	CbGeAlD
Naloxone—Pain—Carboplatin—uterine cancer	0.000573	0.0144	CcSEcCtD
Naloxone—Depression—Progesterone—uterine cancer	0.000551	0.0139	CcSEcCtD
Naloxone—ESR1—uterus—uterine cancer	0.000531	0.0106	CbGeAlD
Naloxone—Body temperature increased—Carboplatin—uterine cancer	0.00053	0.0134	CcSEcCtD
Naloxone—Depression—Medroxyprogesterone Acetate—uterine cancer	0.000499	0.0126	CcSEcCtD
Naloxone—CYP2C8—renal system—uterine cancer	0.000491	0.00977	CbGeAlD
Naloxone—Sweating—Medroxyprogesterone Acetate—uterine cancer	0.00048	0.0121	CcSEcCtD
Naloxone—ESR1—female reproductive system—uterine cancer	0.000478	0.00949	CbGeAlD
Naloxone—CYP2C8—endometrium—uterine cancer	0.000475	0.00944	CbGeAlD
Naloxone—Cardiac disorder—Progesterone—uterine cancer	0.00046	0.0116	CcSEcCtD
Naloxone—Angiopathy—Progesterone—uterine cancer	0.00045	0.0113	CcSEcCtD
Naloxone—Mediastinal disorder—Progesterone—uterine cancer	0.000447	0.0113	CcSEcCtD
Naloxone—ESR1—female gonad—uterine cancer	0.000435	0.00864	CbGeAlD
Naloxone—Mental disorder—Progesterone—uterine cancer	0.000434	0.0109	CcSEcCtD
Naloxone—ESR1—vagina—uterine cancer	0.000432	0.00859	CbGeAlD
Naloxone—Tension—Progesterone—uterine cancer	0.000423	0.0107	CcSEcCtD
Naloxone—Nervousness—Progesterone—uterine cancer	0.000419	0.0106	CcSEcCtD
Naloxone—Cardiac disorder—Medroxyprogesterone Acetate—uterine cancer	0.000417	0.0105	CcSEcCtD
Naloxone—Angiopathy—Medroxyprogesterone Acetate—uterine cancer	0.000408	0.0103	CcSEcCtD
Naloxone—Mediastinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.000405	0.0102	CcSEcCtD
Naloxone—Tremor—Progesterone—uterine cancer	0.000404	0.0102	CcSEcCtD
Naloxone—Chills—Medroxyprogesterone Acetate—uterine cancer	0.000403	0.0102	CcSEcCtD
Naloxone—Mental disorder—Medroxyprogesterone Acetate—uterine cancer	0.000394	0.00992	CcSEcCtD
Naloxone—CYP2C8—female reproductive system—uterine cancer	0.000393	0.00782	CbGeAlD
Naloxone—Tension—Medroxyprogesterone Acetate—uterine cancer	0.000384	0.00967	CcSEcCtD
Naloxone—Nervousness—Medroxyprogesterone Acetate—uterine cancer	0.00038	0.00957	CcSEcCtD
Naloxone—Convulsion—Progesterone—uterine cancer	0.000374	0.00942	CcSEcCtD
Naloxone—Hypertension—Progesterone—uterine cancer	0.000373	0.00939	CcSEcCtD
Naloxone—Tremor—Medroxyprogesterone Acetate—uterine cancer	0.000366	0.00923	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Progesterone—uterine cancer	0.000365	0.00919	CcSEcCtD
Naloxone—Agitation—Medroxyprogesterone Acetate—uterine cancer	0.000359	0.00906	CcSEcCtD
Naloxone—CYP2C8—vagina—uterine cancer	0.000356	0.00707	CbGeAlD
Naloxone—Cardiac arrest—Etoposide—uterine cancer	0.000349	0.00878	CcSEcCtD
Naloxone—Nervous system disorder—Progesterone—uterine cancer	0.000345	0.0087	CcSEcCtD
Naloxone—Tachycardia—Progesterone—uterine cancer	0.000344	0.00866	CcSEcCtD
Naloxone—Skin disorder—Progesterone—uterine cancer	0.000342	0.00862	CcSEcCtD
Naloxone—Hyperhidrosis—Progesterone—uterine cancer	0.00034	0.00858	CcSEcCtD
Naloxone—Convulsion—Medroxyprogesterone Acetate—uterine cancer	0.000339	0.00854	CcSEcCtD
Naloxone—CYP3A4—renal system—uterine cancer	0.000333	0.00661	CbGeAlD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Medroxyprogesterone Acetate—uterine cancer	0.000331	0.00833	CcSEcCtD
Naloxone—ALB—lymph node—uterine cancer	0.000328	0.00651	CbGeAlD
Naloxone—Flushing—Dactinomycin—uterine cancer	0.000325	0.00819	CcSEcCtD
Naloxone—ABCB1—myometrium—uterine cancer	0.000324	0.00643	CbGeAlD
Naloxone—Paraesthesia—Progesterone—uterine cancer	0.000316	0.00797	CcSEcCtD
Naloxone—Chills—Dactinomycin—uterine cancer	0.000314	0.00792	CcSEcCtD
Naloxone—Dyspnoea—Progesterone—uterine cancer	0.000314	0.00791	CcSEcCtD
Naloxone—Nervous system disorder—Medroxyprogesterone Acetate—uterine cancer	0.000313	0.00789	CcSEcCtD
Naloxone—Tachycardia—Medroxyprogesterone Acetate—uterine cancer	0.000311	0.00785	CcSEcCtD
Naloxone—Skin disorder—Medroxyprogesterone Acetate—uterine cancer	0.00031	0.00781	CcSEcCtD
Naloxone—Hyperhidrosis—Medroxyprogesterone Acetate—uterine cancer	0.000309	0.00777	CcSEcCtD
Naloxone—Gastrointestinal disorder—Progesterone—uterine cancer	0.000304	0.00766	CcSEcCtD
Naloxone—Pain—Progesterone—uterine cancer	0.000301	0.00759	CcSEcCtD
Naloxone—Paraesthesia—Medroxyprogesterone Acetate—uterine cancer	0.000287	0.00722	CcSEcCtD
Naloxone—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.000285	0.00717	CcSEcCtD
Naloxone—Ventricular tachycardia—Epirubicin—uterine cancer	0.000283	0.00713	CcSEcCtD
Naloxone—Injection site reaction—Epirubicin—uterine cancer	0.000281	0.00709	CcSEcCtD
Naloxone—ESR1—lymph node—uterine cancer	0.000279	0.00555	CbGeAlD
Naloxone—Abdominal pain—Progesterone—uterine cancer	0.000278	0.00702	CcSEcCtD
Naloxone—Body temperature increased—Progesterone—uterine cancer	0.000278	0.00702	CcSEcCtD
Naloxone—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.000276	0.00694	CcSEcCtD
Naloxone—CYP3A4—female reproductive system—uterine cancer	0.000267	0.0053	CbGeAlD
Naloxone—Ventricular tachycardia—Doxorubicin—uterine cancer	0.000262	0.0066	CcSEcCtD
Naloxone—Injection site reaction—Doxorubicin—uterine cancer	0.00026	0.00656	CcSEcCtD
Naloxone—Coma—Epirubicin—uterine cancer	0.000259	0.00652	CcSEcCtD
Naloxone—ABCB1—epithelium—uterine cancer	0.000254	0.00505	CbGeAlD
Naloxone—Asthenia—Progesterone—uterine cancer	0.000253	0.00637	CcSEcCtD
Naloxone—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.000252	0.00636	CcSEcCtD
Naloxone—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.000252	0.00636	CcSEcCtD
Naloxone—Pulmonary oedema—Epirubicin—uterine cancer	0.000252	0.00635	CcSEcCtD
Naloxone—ABCB1—uterine cervix—uterine cancer	0.000252	0.005	CbGeAlD
Naloxone—Diarrhoea—Progesterone—uterine cancer	0.000241	0.00607	CcSEcCtD
Naloxone—ABCB1—decidua—uterine cancer	0.00024	0.00477	CbGeAlD
Naloxone—Coma—Doxorubicin—uterine cancer	0.000239	0.00603	CcSEcCtD
Naloxone—ABCB1—renal system—uterine cancer	0.000236	0.00468	CbGeAlD
Naloxone—Cardiac disorder—Etoposide—uterine cancer	0.000235	0.00593	CcSEcCtD
Naloxone—Flushing—Etoposide—uterine cancer	0.000235	0.00593	CcSEcCtD
Naloxone—Pulmonary oedema—Doxorubicin—uterine cancer	0.000233	0.00588	CcSEcCtD
Naloxone—Angiopathy—Etoposide—uterine cancer	0.00023	0.0058	CcSEcCtD
Naloxone—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000229	0.00577	CcSEcCtD
Naloxone—Mediastinal disorder—Etoposide—uterine cancer	0.000229	0.00576	CcSEcCtD
Naloxone—ABCB1—endometrium—uterine cancer	0.000228	0.00453	CbGeAlD
Naloxone—Chills—Etoposide—uterine cancer	0.000228	0.00573	CcSEcCtD
Naloxone—Vomiting—Progesterone—uterine cancer	0.000224	0.00564	CcSEcCtD
Naloxone—ABCB1—mammalian vulva—uterine cancer	0.00022	0.00438	CbGeAlD
Naloxone—Hot flush—Epirubicin—uterine cancer	0.00022	0.00554	CcSEcCtD
Naloxone—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000218	0.0055	CcSEcCtD
Naloxone—Menopausal symptoms—Epirubicin—uterine cancer	0.000218	0.00549	CcSEcCtD
Naloxone—Pain—Dactinomycin—uterine cancer	0.000213	0.00536	CcSEcCtD
Naloxone—ABCB1—uterus—uterine cancer	0.00021	0.00417	CbGeAlD
Naloxone—Nausea—Progesterone—uterine cancer	0.000209	0.00527	CcSEcCtD
Naloxone—Hot flush—Doxorubicin—uterine cancer	0.000203	0.00512	CcSEcCtD
Naloxone—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000203	0.00511	CcSEcCtD
Naloxone—Menopausal symptoms—Doxorubicin—uterine cancer	0.000201	0.00508	CcSEcCtD
Naloxone—Abdominal pain—Dactinomycin—uterine cancer	0.000197	0.00496	CcSEcCtD
Naloxone—Body temperature increased—Dactinomycin—uterine cancer	0.000197	0.00496	CcSEcCtD
Naloxone—Cardiac arrest—Epirubicin—uterine cancer	0.000195	0.00492	CcSEcCtD
Naloxone—Convulsion—Etoposide—uterine cancer	0.000191	0.00482	CcSEcCtD
Naloxone—Hypertension—Etoposide—uterine cancer	0.000191	0.0048	CcSEcCtD
Naloxone—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.00019	0.00478	CcSEcCtD
Naloxone—ABCB1—female reproductive system—uterine cancer	0.000189	0.00375	CbGeAlD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000187	0.0047	CcSEcCtD
Naloxone—Nasopharyngitis—Epirubicin—uterine cancer	0.000184	0.00463	CcSEcCtD
Naloxone—Cardiac arrest—Doxorubicin—uterine cancer	0.000181	0.00456	CcSEcCtD
Naloxone—Asthenia—Dactinomycin—uterine cancer	0.000179	0.0045	CcSEcCtD
Naloxone—Tachycardia—Etoposide—uterine cancer	0.000176	0.00443	CcSEcCtD
Naloxone—Skin disorder—Etoposide—uterine cancer	0.000175	0.00441	CcSEcCtD
Naloxone—Hyperhidrosis—Etoposide—uterine cancer	0.000174	0.00439	CcSEcCtD
Naloxone—ABCB1—female gonad—uterine cancer	0.000172	0.00341	CbGeAlD
Naloxone—ABCB1—vagina—uterine cancer	0.000171	0.00339	CbGeAlD
Naloxone—Diarrhoea—Dactinomycin—uterine cancer	0.00017	0.00429	CcSEcCtD
Naloxone—Nasopharyngitis—Doxorubicin—uterine cancer	0.00017	0.00428	CcSEcCtD
Naloxone—Paraesthesia—Etoposide—uterine cancer	0.000162	0.00408	CcSEcCtD
Naloxone—Dyspnoea—Etoposide—uterine cancer	0.000161	0.00405	CcSEcCtD
Naloxone—Vomiting—Dactinomycin—uterine cancer	0.000158	0.00399	CcSEcCtD
Naloxone—Gastrointestinal disorder—Etoposide—uterine cancer	0.000156	0.00392	CcSEcCtD
Naloxone—Pain—Etoposide—uterine cancer	0.000154	0.00388	CcSEcCtD
Naloxone—Sweating—Epirubicin—uterine cancer	0.000152	0.00383	CcSEcCtD
Naloxone—Nausea—Dactinomycin—uterine cancer	0.000148	0.00373	CcSEcCtD
Naloxone—Body temperature increased—Etoposide—uterine cancer	0.000142	0.00359	CcSEcCtD
Naloxone—Abdominal pain—Etoposide—uterine cancer	0.000142	0.00359	CcSEcCtD
Naloxone—Sweating—Doxorubicin—uterine cancer	0.00014	0.00354	CcSEcCtD
Naloxone—Flushing—Epirubicin—uterine cancer	0.000132	0.00332	CcSEcCtD
Naloxone—Cardiac disorder—Epirubicin—uterine cancer	0.000132	0.00332	CcSEcCtD
Naloxone—Asthenia—Etoposide—uterine cancer	0.000129	0.00326	CcSEcCtD
Naloxone—Angiopathy—Epirubicin—uterine cancer	0.000129	0.00325	CcSEcCtD
Naloxone—Mediastinal disorder—Epirubicin—uterine cancer	0.000128	0.00323	CcSEcCtD
Naloxone—Chills—Epirubicin—uterine cancer	0.000128	0.00321	CcSEcCtD
Naloxone—Mental disorder—Epirubicin—uterine cancer	0.000125	0.00314	CcSEcCtD
Naloxone—Diarrhoea—Etoposide—uterine cancer	0.000123	0.00311	CcSEcCtD
Naloxone—Cardiac disorder—Doxorubicin—uterine cancer	0.000122	0.00308	CcSEcCtD
Naloxone—Flushing—Doxorubicin—uterine cancer	0.000122	0.00308	CcSEcCtD
Naloxone—Tension—Epirubicin—uterine cancer	0.000121	0.00306	CcSEcCtD
Naloxone—Nervousness—Epirubicin—uterine cancer	0.00012	0.00303	CcSEcCtD
Naloxone—Angiopathy—Doxorubicin—uterine cancer	0.000119	0.00301	CcSEcCtD
Naloxone—Mediastinal disorder—Doxorubicin—uterine cancer	0.000119	0.00299	CcSEcCtD
Naloxone—Chills—Doxorubicin—uterine cancer	0.000118	0.00297	CcSEcCtD
Naloxone—Mental disorder—Doxorubicin—uterine cancer	0.000115	0.0029	CcSEcCtD
Naloxone—Vomiting—Etoposide—uterine cancer	0.000115	0.00289	CcSEcCtD
Naloxone—Agitation—Epirubicin—uterine cancer	0.000114	0.00287	CcSEcCtD
Naloxone—Tension—Doxorubicin—uterine cancer	0.000112	0.00283	CcSEcCtD
Naloxone—Nervousness—Doxorubicin—uterine cancer	0.000111	0.0028	CcSEcCtD
Naloxone—ABCB1—lymph node—uterine cancer	0.00011	0.00219	CbGeAlD
Naloxone—Convulsion—Epirubicin—uterine cancer	0.000107	0.0027	CcSEcCtD
Naloxone—Nausea—Etoposide—uterine cancer	0.000107	0.0027	CcSEcCtD
Naloxone—Hypertension—Epirubicin—uterine cancer	0.000107	0.00269	CcSEcCtD
Naloxone—Agitation—Doxorubicin—uterine cancer	0.000105	0.00265	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000105	0.00264	CcSEcCtD
Naloxone—Convulsion—Doxorubicin—uterine cancer	9.92e-05	0.0025	CcSEcCtD
Naloxone—Nervous system disorder—Epirubicin—uterine cancer	9.9e-05	0.0025	CcSEcCtD
Naloxone—Hypertension—Doxorubicin—uterine cancer	9.88e-05	0.00249	CcSEcCtD
Naloxone—Tachycardia—Epirubicin—uterine cancer	9.86e-05	0.00248	CcSEcCtD
Naloxone—Skin disorder—Epirubicin—uterine cancer	9.81e-05	0.00247	CcSEcCtD
Naloxone—Hyperhidrosis—Epirubicin—uterine cancer	9.76e-05	0.00246	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	9.68e-05	0.00244	CcSEcCtD
Naloxone—Nervous system disorder—Doxorubicin—uterine cancer	9.16e-05	0.00231	CcSEcCtD
Naloxone—Tachycardia—Doxorubicin—uterine cancer	9.12e-05	0.0023	CcSEcCtD
Naloxone—Skin disorder—Doxorubicin—uterine cancer	9.08e-05	0.00229	CcSEcCtD
Naloxone—Paraesthesia—Epirubicin—uterine cancer	9.07e-05	0.00229	CcSEcCtD
Naloxone—Hyperhidrosis—Doxorubicin—uterine cancer	9.03e-05	0.00228	CcSEcCtD
Naloxone—Dyspnoea—Epirubicin—uterine cancer	9e-05	0.00227	CcSEcCtD
Naloxone—Gastrointestinal disorder—Epirubicin—uterine cancer	8.72e-05	0.0022	CcSEcCtD
Naloxone—Pain—Epirubicin—uterine cancer	8.64e-05	0.00218	CcSEcCtD
Naloxone—Paraesthesia—Doxorubicin—uterine cancer	8.39e-05	0.00211	CcSEcCtD
Naloxone—Dyspnoea—Doxorubicin—uterine cancer	8.33e-05	0.0021	CcSEcCtD
Naloxone—Gastrointestinal disorder—Doxorubicin—uterine cancer	8.07e-05	0.00203	CcSEcCtD
Naloxone—Pain—Doxorubicin—uterine cancer	7.99e-05	0.00201	CcSEcCtD
Naloxone—Abdominal pain—Epirubicin—uterine cancer	7.98e-05	0.00201	CcSEcCtD
Naloxone—Body temperature increased—Epirubicin—uterine cancer	7.98e-05	0.00201	CcSEcCtD
Naloxone—Abdominal pain—Doxorubicin—uterine cancer	7.39e-05	0.00186	CcSEcCtD
Naloxone—Body temperature increased—Doxorubicin—uterine cancer	7.39e-05	0.00186	CcSEcCtD
Naloxone—Asthenia—Epirubicin—uterine cancer	7.25e-05	0.00183	CcSEcCtD
Naloxone—Diarrhoea—Epirubicin—uterine cancer	6.91e-05	0.00174	CcSEcCtD
Naloxone—Asthenia—Doxorubicin—uterine cancer	6.7e-05	0.00169	CcSEcCtD
Naloxone—Vomiting—Epirubicin—uterine cancer	6.42e-05	0.00162	CcSEcCtD
Naloxone—Diarrhoea—Doxorubicin—uterine cancer	6.39e-05	0.00161	CcSEcCtD
Naloxone—Nausea—Epirubicin—uterine cancer	6e-05	0.00151	CcSEcCtD
Naloxone—Vomiting—Doxorubicin—uterine cancer	5.94e-05	0.0015	CcSEcCtD
Naloxone—Nausea—Doxorubicin—uterine cancer	5.55e-05	0.0014	CcSEcCtD
Naloxone—OPRD1—GPCR downstream signaling—CXCL8—uterine cancer	1.49e-05	0.000187	CbGpPWpGaD
Naloxone—ALB—Platelet activation, signaling and aggregation—VEGFA—uterine cancer	1.47e-05	0.000185	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—KRAS—uterine cancer	1.47e-05	0.000184	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—POLD1—uterine cancer	1.46e-05	0.000183	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—FBXW7—uterine cancer	1.46e-05	0.000182	CbGpPWpGaD
Naloxone—ALB—Metabolism—POLD1—uterine cancer	1.45e-05	0.000182	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	1.45e-05	0.000182	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—AKR1C3—uterine cancer	1.45e-05	0.000182	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—SMAD3—uterine cancer	1.42e-05	0.000178	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—HRAS—uterine cancer	1.42e-05	0.000177	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PGR—uterine cancer	1.41e-05	0.000177	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—KRAS—uterine cancer	1.41e-05	0.000177	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—SMAD3—uterine cancer	1.41e-05	0.000177	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—SOCS3—uterine cancer	1.41e-05	0.000177	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—SMAD3—uterine cancer	1.41e-05	0.000176	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—SRD5A2—uterine cancer	1.38e-05	0.000173	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—NDUFB11—uterine cancer	1.38e-05	0.000173	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—AKR1C1—uterine cancer	1.37e-05	0.000171	CbGpPWpGaD
Naloxone—ALB—Metabolism—AKR1C1—uterine cancer	1.36e-05	0.00017	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—CXCL8—uterine cancer	1.36e-05	0.00017	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—CXCL8—uterine cancer	1.35e-05	0.000169	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CDKN2B—uterine cancer	1.35e-05	0.000169	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—PIK3CA—uterine cancer	1.35e-05	0.000169	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—YWHAE—uterine cancer	1.35e-05	0.000169	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—FGFR2—uterine cancer	1.35e-05	0.000169	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—FGFR2—uterine cancer	1.34e-05	0.000168	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IGF1R—uterine cancer	1.31e-05	0.000164	CbGpPWpGaD
Naloxone—CREB1—Immune System—ERBB2—uterine cancer	1.31e-05	0.000164	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—CXCL8—uterine cancer	1.31e-05	0.000164	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—PIK3CA—uterine cancer	1.3e-05	0.000162	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—FBXW7—uterine cancer	1.29e-05	0.000162	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—POLD1—uterine cancer	1.27e-05	0.00016	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—STK11—uterine cancer	1.27e-05	0.000159	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—CCL2—uterine cancer	1.27e-05	0.000159	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—MTHFR—uterine cancer	1.25e-05	0.000157	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—HRAS—uterine cancer	1.25e-05	0.000156	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—AKT1—uterine cancer	1.25e-05	0.000156	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—SMAD3—uterine cancer	1.23e-05	0.000154	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	1.23e-05	0.000154	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—RRM2—uterine cancer	1.22e-05	0.000153	CbGpPWpGaD
Naloxone—ALB—Metabolism—RRM2—uterine cancer	1.21e-05	0.000152	CbGpPWpGaD
Naloxone—CREB1—Immune System—CDKN1B—uterine cancer	1.21e-05	0.000152	CbGpPWpGaD
Naloxone—CREB1—Disease—ERBB2—uterine cancer	1.21e-05	0.000151	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—HRAS—uterine cancer	1.2e-05	0.00015	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—SOCS3—uterine cancer	1.19e-05	0.000149	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—AKR1C1—uterine cancer	1.19e-05	0.000149	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—CXCL8—uterine cancer	1.19e-05	0.000149	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—DCN—uterine cancer	1.18e-05	0.000148	CbGpPWpGaD
Naloxone—ALB—Metabolism—DCN—uterine cancer	1.18e-05	0.000147	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—FGFR2—uterine cancer	1.18e-05	0.000147	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—ESR1—uterine cancer	1.15e-05	0.000144	CbGpPWpGaD
Naloxone—ALB—Platelet activation, signaling and aggregation—PIK3CA—uterine cancer	1.15e-05	0.000144	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—ESR1—uterine cancer	1.15e-05	0.000144	CbGpPWpGaD
Naloxone—CREB1—Immune System—CTNNB1—uterine cancer	1.14e-05	0.000143	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CDKN2B—uterine cancer	1.14e-05	0.000143	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	1.13e-05	0.000142	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—STK11—uterine cancer	1.13e-05	0.000141	CbGpPWpGaD
Naloxone—CREB1—Disease—CDKN1B—uterine cancer	1.12e-05	0.00014	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CYP11A1—uterine cancer	1.12e-05	0.00014	CbGpPWpGaD
Naloxone—CREB1—Immune System—PTEN—uterine cancer	1.12e-05	0.00014	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IGF1R—uterine cancer	1.11e-05	0.000139	CbGpPWpGaD
Naloxone—ALB—Metabolism—CYP11A1—uterine cancer	1.11e-05	0.000139	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.11e-05	0.000138	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—CXCL8—uterine cancer	1.1e-05	0.000138	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—AKT1—uterine cancer	1.1e-05	0.000138	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	1.1e-05	0.000137	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—NRAS—uterine cancer	1.09e-05	0.000136	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—NRAS—uterine cancer	1.09e-05	0.000136	CbGpPWpGaD
Naloxone—CREB1—Immune System—EP300—uterine cancer	1.06e-05	0.000133	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—RRM2—uterine cancer	1.06e-05	0.000133	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—AKT1—uterine cancer	1.06e-05	0.000133	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—SOCS3—uterine cancer	1.06e-05	0.000132	CbGpPWpGaD
Naloxone—CREB1—Disease—CTNNB1—uterine cancer	1.06e-05	0.000132	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—AKR1C3—uterine cancer	1.05e-05	0.000132	CbGpPWpGaD
Naloxone—ALB—Metabolism—AKR1C3—uterine cancer	1.05e-05	0.000131	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—SMAD3—uterine cancer	1.04e-05	0.000131	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—DCN—uterine cancer	1.03e-05	0.000129	CbGpPWpGaD
Naloxone—CREB1—Disease—PTEN—uterine cancer	1.03e-05	0.000129	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CCL2—uterine cancer	1.01e-05	0.000127	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CDKN2B—uterine cancer	1.01e-05	0.000127	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CCL2—uterine cancer	1.01e-05	0.000127	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—ESR1—uterine cancer	1.01e-05	0.000126	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—CXCL8—uterine cancer	1e-05	0.000126	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—STAR—uterine cancer	1e-05	0.000125	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—AKR1B1—uterine cancer	1e-05	0.000125	CbGpPWpGaD
Naloxone—CREB1—Immune System—NRAS—uterine cancer	9.95e-06	0.000125	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—FGFR2—uterine cancer	9.95e-06	0.000125	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IGF1R—uterine cancer	9.84e-06	0.000123	CbGpPWpGaD
Naloxone—CREB1—Disease—EP300—uterine cancer	9.82e-06	0.000123	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CYP11A1—uterine cancer	9.72e-06	0.000122	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—NRAS—uterine cancer	9.52e-06	0.000119	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—PIK3CA—uterine cancer	9.45e-06	0.000118	CbGpPWpGaD
Naloxone—ALB—Platelet activation, signaling and aggregation—AKT1—uterine cancer	9.41e-06	0.000118	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—KRAS—uterine cancer	9.37e-06	0.000117	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—KRAS—uterine cancer	9.34e-06	0.000117	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	9.26e-06	0.000116	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—SMAD3—uterine cancer	9.25e-06	0.000116	CbGpPWpGaD
Naloxone—CREB1—Disease—NRAS—uterine cancer	9.19e-06	0.000115	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—AKR1C3—uterine cancer	9.18e-06	0.000115	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CCL2—uterine cancer	8.87e-06	0.000111	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—FGFR2—uterine cancer	8.82e-06	0.00011	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—PIK3CA—uterine cancer	8.61e-06	0.000108	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—PIK3CA—uterine cancer	8.58e-06	0.000107	CbGpPWpGaD
Naloxone—CREB1—Immune System—KRAS—uterine cancer	8.56e-06	0.000107	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—ESR1—uterine cancer	8.51e-06	0.000107	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—ERBB2—uterine cancer	8.46e-06	0.000106	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—ERBB2—uterine cancer	8.43e-06	0.000106	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—PIK3CA—uterine cancer	8.29e-06	0.000104	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CYP19A1—uterine cancer	8.21e-06	0.000103	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—STK11—uterine cancer	8.21e-06	0.000103	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—KRAS—uterine cancer	8.19e-06	0.000103	CbGpPWpGaD
Naloxone—ALB—Metabolism—STK11—uterine cancer	8.16e-06	0.000102	CbGpPWpGaD
Naloxone—ALB—Metabolism—CYP19A1—uterine cancer	8.16e-06	0.000102	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—NRAS—uterine cancer	8.05e-06	0.000101	CbGpPWpGaD
Naloxone—ALB—Hemostasis—EP300—uterine cancer	8.02e-06	0.0001	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CXCL8—uterine cancer	8.02e-06	0.0001	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CXCL8—uterine cancer	7.99e-06	0.0001	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—HRAS—uterine cancer	7.97e-06	9.97e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—HRAS—uterine cancer	7.94e-06	9.94e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—KRAS—uterine cancer	7.91e-06	9.9e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—PIK3CA—uterine cancer	7.87e-06	9.85e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—POLD1—uterine cancer	7.85e-06	9.83e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CDKN1B—uterine cancer	7.83e-06	9.8e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CDKN1B—uterine cancer	7.81e-06	9.77e-05	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—AKT1—uterine cancer	7.72e-06	9.67e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	7.7e-06	9.64e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	7.66e-06	9.59e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—VEGFA—uterine cancer	7.6e-06	9.51e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—PIK3CA—uterine cancer	7.53e-06	9.42e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—NRAS—uterine cancer	7.51e-06	9.39e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CCL2—uterine cancer	7.49e-06	9.38e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CTNNB1—uterine cancer	7.4e-06	9.26e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—ERBB2—uterine cancer	7.39e-06	9.25e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CTNNB1—uterine cancer	7.38e-06	9.23e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—EP300—uterine cancer	7.35e-06	9.19e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—AKR1C1—uterine cancer	7.34e-06	9.19e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—EP300—uterine cancer	7.3e-06	9.14e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—HRAS—uterine cancer	7.28e-06	9.11e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—PIK3CA—uterine cancer	7.27e-06	9.09e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—PTEN—uterine cancer	7.21e-06	9.03e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—PTEN—uterine cancer	7.19e-06	9e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—STK11—uterine cancer	7.15e-06	8.95e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CYP19A1—uterine cancer	7.15e-06	8.95e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—AKT1—uterine cancer	7.04e-06	8.81e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—AKT1—uterine cancer	7.01e-06	8.78e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CXCL8—uterine cancer	7.01e-06	8.77e-05	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—PIK3CA—uterine cancer	7.01e-06	8.77e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PTEN—uterine cancer	6.98e-06	8.74e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—HRAS—uterine cancer	6.96e-06	8.72e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—KRAS—uterine cancer	6.92e-06	8.67e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—EP300—uterine cancer	6.88e-06	8.61e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—EP300—uterine cancer	6.86e-06	8.58e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CDKN1B—uterine cancer	6.85e-06	8.57e-05	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—AKT1—uterine cancer	6.77e-06	8.48e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—HRAS—uterine cancer	6.72e-06	8.41e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—EP300—uterine cancer	6.66e-06	8.33e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CCL2—uterine cancer	6.64e-06	8.32e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—RRM2—uterine cancer	6.55e-06	8.19e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—VEGFA—uterine cancer	6.51e-06	8.15e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—VEGFA—uterine cancer	6.49e-06	8.13e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CTNNB1—uterine cancer	6.47e-06	8.09e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—KRAS—uterine cancer	6.46e-06	8.09e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—NRAS—uterine cancer	6.43e-06	8.05e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—AKT1—uterine cancer	6.43e-06	8.05e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—NRAS—uterine cancer	6.41e-06	8.03e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—PIK3CA—uterine cancer	6.36e-06	7.96e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—DCN—uterine cancer	6.35e-06	7.95e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PTEN—uterine cancer	6.3e-06	7.89e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—ERBB2—uterine cancer	6.25e-06	7.82e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—MTHFR—uterine cancer	6.17e-06	7.72e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—AKT1—uterine cancer	6.15e-06	7.7e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—MTHFR—uterine cancer	6.13e-06	7.67e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—EP300—uterine cancer	6.01e-06	7.52e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CYP11A1—uterine cancer	5.99e-06	7.49e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—PIK3CA—uterine cancer	5.94e-06	7.43e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—AKT1—uterine cancer	5.93e-06	7.43e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CXCL8—uterine cancer	5.92e-06	7.41e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—HRAS—uterine cancer	5.89e-06	7.37e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CDKN1B—uterine cancer	5.79e-06	7.24e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—TP53—uterine cancer	5.74e-06	7.19e-05	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—AKT1—uterine cancer	5.72e-06	7.16e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—VEGFA—uterine cancer	5.69e-06	7.13e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—AKR1C3—uterine cancer	5.65e-06	7.08e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—NRAS—uterine cancer	5.62e-06	7.04e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—ERBB2—uterine cancer	5.54e-06	6.93e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—KRAS—uterine cancer	5.54e-06	6.93e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—KRAS—uterine cancer	5.52e-06	6.91e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—HRAS—uterine cancer	5.49e-06	6.87e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CTNNB1—uterine cancer	5.47e-06	6.84e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	5.43e-06	6.8e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	5.4e-06	6.76e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—MTHFR—uterine cancer	5.37e-06	6.72e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PTEN—uterine cancer	5.33e-06	6.67e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CXCL8—uterine cancer	5.25e-06	6.57e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—AKT1—uterine cancer	5.2e-06	6.5e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CDKN1B—uterine cancer	5.13e-06	6.42e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—PIK3CA—uterine cancer	5.09e-06	6.37e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—EP300—uterine cancer	5.08e-06	6.36e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—PIK3CA—uterine cancer	5.07e-06	6.35e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PIK3CA—uterine cancer	4.93e-06	6.16e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—TP53—uterine cancer	4.92e-06	6.16e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—TP53—uterine cancer	4.91e-06	6.14e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—AKT1—uterine cancer	4.85e-06	6.07e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CTNNB1—uterine cancer	4.85e-06	6.07e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—KRAS—uterine cancer	4.84e-06	6.06e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—VEGFA—uterine cancer	4.81e-06	6.02e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—NRAS—uterine cancer	4.75e-06	5.95e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PTEN—uterine cancer	4.72e-06	5.91e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—HRAS—uterine cancer	4.71e-06	5.89e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—HRAS—uterine cancer	4.69e-06	5.87e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—EP300—uterine cancer	4.5e-06	5.64e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PIK3CA—uterine cancer	4.45e-06	5.57e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CYP19A1—uterine cancer	4.4e-06	5.51e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—STK11—uterine cancer	4.4e-06	5.51e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—TP53—uterine cancer	4.3e-06	5.38e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—VEGFA—uterine cancer	4.27e-06	5.34e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—NRAS—uterine cancer	4.21e-06	5.27e-05	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—AKT1—uterine cancer	4.19e-06	5.24e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—AKT1—uterine cancer	4.16e-06	5.2e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—AKT1—uterine cancer	4.14e-06	5.19e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—HRAS—uterine cancer	4.11e-06	5.15e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—KRAS—uterine cancer	4.09e-06	5.12e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—AKT1—uterine cancer	4.02e-06	5.04e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PIK3CA—uterine cancer	3.76e-06	4.7e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—TP53—uterine cancer	3.64e-06	4.55e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—AKT1—uterine cancer	3.63e-06	4.55e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—KRAS—uterine cancer	3.63e-06	4.54e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—HRAS—uterine cancer	3.48e-06	4.35e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PTEN—uterine cancer	3.43e-06	4.29e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PTEN—uterine cancer	3.41e-06	4.27e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PIK3CA—uterine cancer	3.33e-06	4.17e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—MTHFR—uterine cancer	3.31e-06	4.14e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—EP300—uterine cancer	3.27e-06	4.09e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—EP300—uterine cancer	3.25e-06	4.07e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TP53—uterine cancer	3.22e-06	4.03e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—HRAS—uterine cancer	3.08e-06	3.86e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—AKT1—uterine cancer	3.07e-06	3.84e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PTEN—uterine cancer	2.99e-06	3.74e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—EP300—uterine cancer	2.85e-06	3.57e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—AKT1—uterine cancer	2.72e-06	3.41e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PIK3CA—uterine cancer	2.42e-06	3.03e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PIK3CA—uterine cancer	2.41e-06	3.01e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PIK3CA—uterine cancer	2.11e-06	2.64e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—AKT1—uterine cancer	1.98e-06	2.47e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—AKT1—uterine cancer	1.97e-06	2.46e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PTEN—uterine cancer	1.84e-06	2.3e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—EP300—uterine cancer	1.76e-06	2.2e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—AKT1—uterine cancer	1.72e-06	2.16e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PIK3CA—uterine cancer	1.3e-06	1.63e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—AKT1—uterine cancer	1.06e-06	1.33e-05	CbGpPWpGaD
